1. CAR-Macrophage Therapy Alleviates Myocardial Ischemia-Reperfusion Injury.
- Author
-
Wang J, Du H, Xie W, Bi J, Zhang H, Liu X, Wang Y, Zhang S, Lei A, He C, Yuan H, Zhang J, Li Y, Xu P, Liu S, Zhou Y, Shen J, Wu J, Cai Y, Yang C, Li Z, Liang Y, Zhao Y, Zhang J, and Song M
- Subjects
- Animals, Mice, Male, Receptors, Chimeric Antigen metabolism, Myocardium pathology, Myocardium metabolism, Membrane Proteins metabolism, Membrane Proteins genetics, Gelatinases metabolism, Serine Endopeptidases metabolism, Phagocytosis, Cells, Cultured, Myocardial Reperfusion Injury pathology, Myocardial Reperfusion Injury metabolism, Myocardial Reperfusion Injury therapy, Myocardial Reperfusion Injury prevention & control, Macrophages metabolism, Fibroblasts metabolism, Fibroblasts pathology, Fibrosis, Mice, Inbred C57BL, Endopeptidases metabolism
- Abstract
Background: Given the growing acknowledgment of the detrimental effects of excessive myocardial fibrosis on pathological remodeling after myocardial ischemia-reperfusion injury (I/R), targeting the modulation of myocardial fibrosis may offer protective and therapeutic advantages. However, effective clinical interventions and therapies that target myocardial fibrosis remain limited. As a promising chimeric antigen receptor (CAR) cell therapy, whether CAR macrophages (CAR-Ms) can be used to treat I/R remains unclear., Methods: The expression of FAP (fibroblast activation protein) was studied in mouse hearts after I/R. FAP CAR-Ms were generated to target FAP-expressing cardiac fibroblasts in mouse hearts after I/R. The phagocytosis activity of FAP CAR-Ms was tested in vitro. The efficacy and safety of FAP CAR-Ms in treating I/R were evaluated in vivo., Results: FAP was significantly upregulated in activated cardiac fibroblasts as early as 3 days after I/R. Upon demonstrating their ability to engulf FAP-overexpressing fibroblasts, we intravenously administered FAP CAR-Ms to mice at 3 days after I/R and found that FAP CAR-Ms significantly improved cardiac function and reduced myocardial fibrosis in mice after I/R. No toxicities associated with FAP CAR-Ms were detected in the heart or other organs at 2 weeks after I/R. Finally, we found that FAP CAR-Ms conferred long-term cardioprotection against I/R., Conclusions: Our proof-of-concept study demonstrates the therapeutic potential of FAP CAR-Ms in alleviating myocardial I/R and potentially opens new avenues for the treatment of a range of heart diseases that include a fibrotic phenotype., Competing Interests: None.
- Published
- 2024
- Full Text
- View/download PDF